Targeted polymeric nanoparticles for brain delivery of high molecular weight molecules in lysosomal storage disorders

PLoS ONE

Volumn 11, Issue 5, 2016, Pages

  Salvalaio, Marika ^a,c   Rigon, Laura ^a   Belletti, Daniela ^b   D'Avanzo, Francesca ^a,d   Pederzoli, Francesca ^b,c   Ruozi, Barbara ^b   Marin, Oriano ^a   Vandelli, Maria Angela ^b   Forni, Flavio ^b   Scarpa, Maurizio ^a,d   Tomanin, Rosella ^a   Tosi, Giovanni ^b  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c Foundation Institute of Pediatric Research Citt della Speranza   (Italy)

^d Brains for Brain Foundation   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLE; POLYGLACTIN; ALBUMINOID; DRUG CARRIER; FLUORESCEIN ISOTHIOCYANATE; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; HUNTER SYNDROME; HURLER SYNDROME; IN VIVO STUDY; LYSOSOME STORAGE DISEASE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; WILD TYPE; ANIMAL; CHEMISTRY; DISEASE MODEL; ENZYME REPLACEMENT; GENETICS; KNOCKOUT MOUSE; METABOLISM; MUCOPOLYSACCHARIDOSIS I; MUCOPOLYSACCHARIDOSIS II; PATHOLOGY; PROCEDURES;

ALBUMINS; ANIMALS; BLOOD-BRAIN BARRIER; DISEASE MODELS, ANIMAL; DRUG CARRIERS; ENZYME REPLACEMENT THERAPY; FLUORESCEIN-5-ISOTHIOCYANATE; LACTIC ACID; MICE; MICE, KNOCKOUT; MUCOPOLYSACCHARIDOSIS I; MUCOPOLYSACCHARIDOSIS II; NANOPARTICLES; POLYGLYCOLIC ACID;

EID: 84971254208     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0156452     Document Type: Article

References (43)

1. Fuller M, Meikle PJ, Hopwood JJ. Epidemiology of lysosomal storage diseases: an overview. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Fabry Disease: Perspectives from 5 Years of FOS. Oxford: Oxford PharmaGenesis; 2006.
2. Sands MS, Haskins ME. CNS-directed gene therapy for lysosomal storage diseases. Acta Paediatr. 2008; 97: 22-27. doi: 10.1111/j.1651-2227.2008.00660.x PMID: 18339183
3. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, et al, editors. The Metabolic and Molecular Bases of Inherited Disease. New York (NY): McGraw-Hill; 2001. pp. 3421-3452.
4. Clarke LA. Mucopolysaccharidosis Type I. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al, editors. GeneReviews(R). Seattle (WA): University of Washington, Seattle; 1993.
5. Scarpa M. Mucopolysaccharidosis Type II. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al, editors. GeneReviews(R). Seattle (WA): University of Washington, Seattle; 1993.
6. Bove KE, Daugherty C, Grabowski GA. Pathological findings in Gaucher disease type 2 patients following enzyme therapy. Hum Pathol. 1995; 26: 1040-1045. PMID: 7672788
7. Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH. Convection-enhanced delivery of macromolecules in the brain. Proc Natl Acad Sci U S A. 1994; 91: 2076-2080. PMID: 8134351
8. Kroll RA, Pagel MA, Muldoon LL, Roman-Goldstein S, Neuwelt EA. Increasing volume of distribution to the brain with interstitial infusion: dose, rather than convection, might be the most important factor. Neurosurgery. 1996; 38: 746-52; discussion 752-4. PMID: 8692395
9. Siegal T, Rubinstein R, Bokstein F, Schwartz A, Lossos A, Shalom E, et al. In vivo assessment of the window of barrier opening after osmotic blood-brain barrier disruption in humans. J Neurosurg. 2000; 92: 599-605. PMID: 10761648
10. Kabanov AV, Gendelman HE. Nanomedicine in the diagnosis and therapy of neurodegenerative disorders. Prog Polym Sci. 2007; 32: 1054-1082. PMID: 20234846
11. Tosi G, Costantino L, Ruozi B, Forni F, Vandelli MA. Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opin Drug Deliv. 2008; 5: 155-174. doi: 10.1517/17425247.5.2.155 PMID: 18248316
12. Kreuter J. Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? Adv Drug Deliv Rev. 2014; 71: 2-14. doi: 10.1016/j.addr.2013.08.008 PMID: 23981489
13. Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. J Control Release. 2012; 161: 264-273. doi: 10.1016/j.jconrel.2011.08.017 PMID: 21872624
14. Vilella A, Tosi G, Grabrucker AM, Ruozi B, Belletti D, Vandelli MA, et al. Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution. J Control Release. 2014; 174: 195-201. doi: 10.1016/j.jconrel.2013.11.023 PMID: 24316476
15. Tosi G, Vilella A, Chhabra R, Schmeisser MJ, Boeckers TM, Ruozi B, et al. Insight on the fate of CNS-targeted nanoparticles. Part II: Intercellular neuronal cell-to-cell transport. J Control Release. 2014; 177: 96-107. doi: 10.1016/j.jconrel.2014.01.004 PMID: 24417968
16. Tosi G, Ruozi B, Belletti D, Vilella A, Zoli M, Vandelli MA, et al. Brain-targeted polymeric nanoparticles: in vivo evidence of different routes of administration in rodents. Nanomedicine (Lond). 2013; 8: 1373-1383.
17. Tosi G, Costantino L, Rivasi F, Ruozi B, Leo E, Vergoni AV, et al. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control Release. 2007; 122: 1-9. PMID: 17651855
18. Tosi G, Fano RA, Bondioli L, Badiali L, Benassi R, Rivasi F, et al. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier. Nanomedicine (Lond). 2011; 6: 423-436.
19. Chhabra R, Grabrucker AM, Veratti P, Belletti D, Boeckers TM, Vandelli MA, et al. Characterization of lysosome-destabilizing DOPE/PLGA nanoparticles designed for cytoplasmic drug release. Int J Pharm. 2014; 471: 349-357. doi: 10.1016/j.ijpharm.2014.05.054 PMID: 24882034
20. Boyle J. BIND Therapeutics Reports Phase 2 Data from iNSITE 1 and iNSITE 2 Trials with BIND-014 and Provides Strategic Update. Available: http://ir.bindtherapeutics.com/releasedetail.cfm?ReleaseID=963798.
21. Lu JM, Wang X, Marin-Muller C, Wang H, Lin PH, Yao Q, et al. Current advances in research and clinical applications of PLGA-based nanotechnology. Expert Rev Mol Diagn. 2009; 9: 325-341. doi: 10.1586/erm.09.15 PMID: 19435455
22. Valencia PM, Hanewich-Hollatz MH, Gao W, Karim F, Langer R, Karnik R, et al. Effects of ligands with different water solubilities on self-assembly and properties of targeted nanoparticles. Biomaterials. 2011; 32: 6226-6233. doi: 10.1016/j.biomaterials.2011.04.078 PMID: 21658757
23. Werner ME, Cummings ND, Sethi M, Wang EC, Sukumar R, Moore DT, et al. Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013; 86: 463-468. doi: 10.1016/j.ijrobp.2013.02.009 PMID: 23708084
24. Ohmi K, Greenberg DS, Rajavel KS, Ryazantsev S, Li HH, Neufeld EF. Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB. Proc Natl Acad Sci U S A. 2003; 100: 1902-1907. PMID: 12576554
25. Friso A, Tomanin R, Alba S, Gasparotto N, Puicher EP, Fusco M, et al. Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts. J Gene Med. 2005; 7: 1482-1491. PMID: 15966019
26. Cardone M, Polito VA, Pepe S, Mann L, D'Azzo A, Auricchio A, et al. Correction of Hunter syndrome in the MPSII mouse model by AAV2/8-mediated gene delivery. Hum Mol Genet. 2006; 15: 1225-1236. PMID: 16505002
27. Garcia AR, Pan J, Lamsa JC, Muenzer J. The characterization of a murine model of mucopolysaccharidosis II (Hunter syndrome). J Inherit Metab Dis. 2007; 30: 924-934. PMID: 17876721
28. Bondioli L, Costantino L, Ballestrazzi A, Lucchesi D, Boraschi D, Pellati F, et al. PLGA nanoparticles surface decorated with the sialic acid, N-acetylneuraminic acid. Biomaterials. 2010; 31: 3395-3403. doi: 10.1016/j.biomaterials.2010.01.049 PMID: 20132980
29. Rosca ID, Watari F, Uo M. Microparticle formation and its mechanism in single and double emulsion solvent evaporation. J Control Release. 2004; 99: 271-280. PMID: 15380636
30. Ruozi B, Belletti D, Forni F, Sharma A, Muresanu D, Mossler H, et al. Poly (D,L-lactide-co-glycolide) nanoparticles loaded with cerebrolysin display neuroprotective activity in a rat model of concussive head injury. CNS Neurol Disord Drug Targets. 2014; 13: 1475-1482. PMID: 25106629
31. Nobs L, Buchegger F, Gurny R, Allemann E. Poly(lactic acid) nanoparticles labeled with biologically active Neutravidin for active targeting. Eur J Pharm Biopharm. 2004; 58: 483-490. PMID: 15451522
32. Date PV, Samad A, Devarajan PV. Freeze thaw: a simple approach for prediction of optimal cryoprotectant for freeze drying. AAPS PharmSciTech. 2010; 11: 304-313. doi: 10.1208/s12249-010-9382-3 PMID: 20182826
33. Liu Y, Li K, Pan J, Liu B, Feng SS. Folic acid conjugated nanoparticles of mixed lipid monolayer shell and biodegradable polymer core for targeted delivery of Docetaxel. Biomaterials. 2010; 31: 330-338. doi: 10.1016/j.biomaterials.2009.09.036 PMID: 19783040
34. Tosi G, Bondioli L, Ruozi B, Badiali L, Severini GM, Biffi S, et al. NIR-labeled nanoparticles engineered for brain targeting: in vivo optical imaging application and fluorescent microscopy evidences. J Neural Transm (Vienna). 2011; 118: 145-153.
35. Schindelin J, Arganda-Carreras I, Frise E, Kaynig V, Longair M, Pietzsch T, et al. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012; 9: 676-682. doi: 10.1038/nmeth.2019 PMID: 22743772
36. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005; 2: 3-14. PMID: 15717053
37. Bondioli L, Ludovisi A, Tosi G, Ruozi B, Forni F, Pozio E, et al. The loading of labelled antibody-engineered nanoparticles with Indinavir increases its in vitro efficacy against Cryptosporidium parvum. Parasitology. 2011; 138: 1384-1391. doi: 10.1017/S0031182011001119 PMID: 21819637
38. Garbuzova-Davis S, Louis MK, Haller EM, Derasari HM, Rawls AE, Sanberg PR. Blood-brain barrier impairment in an animal model of MPS III B. PLoS One. 2011; 6: e16601. doi: 10.1371/journal.pone.0016601 PMID: 21408219
39. Garbuzova-Davis S, Mirtyl S, Sallot SA, Hernandez-Ontiveros DG, Haller E, Sanberg PR. Blood-brain barrier impairment in MPS III patients. BMC Neurol. 2013; 13: 174-2377-13-174.
40. Wang D, El-Amouri SS, Dai M, Kuan CY, Hui DY, Brady RO, et al. Engineering a lysosomal enzyme with a derivative of receptor-binding domain of apoE enables delivery across the blood-brain barrier. Proc Natl Acad Sci U S A. 2013; 110: 2999-3004. doi: 10.1073/pnas.1222742110 PMID: 23382178
41. Jeyakumar M, Thomas R, Elliot-Smith E, Smith DA, van der Spoel AC, d'Azzo A, et al. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain. 2003; 126: 974-987. PMID: 12615653
42. Vitner EB, Farfel-Becker T, Eilam R, Biton I, Futerman AH. Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease. Brain. 2012; 135: 1724-1735. doi: 10.1093/brain/aws095 PMID: 22566609
43. Begley DJ, Pontikis CC, Scarpa M. Lysosomal storage diseases and the blood-brain barrier. Curr Pharm Des. 2008; 14: 1566-1580. PMID: 18673198